Globus Medical (GMED) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aegis Capital Reiterates Buy on Globus Medical (GMED) Following 4Q EPS Miss
February 28, 2017 7:45 AM ESTAegis Capital reiterated a Buy rating and $31.00 price target on Globus Medical (NYSE: GMED) following the company's 4Q earnings report. Sales grew 6.3% to $151.6 million, driven by Alphatec international sales and recovery in the US market. Non-GAAP EPS of $0.31 was 2 cents short of consensus estimates. Management reiterated FY2017 guidance of $625 million (including a $5 million FX headwind) and non-GAAP EPS of... More
